Concepedia

Whitney S. Helms

WS

Statistics

Publications

24

Citations

5.4K

H-Index

23

Active since

1999

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

University of North Carolina at Chapel Hill

Center for Devices and Radiological Health

Emory University

Whitney S. Helms is an author at Center for Drug Evaluation and Research specializing in medicine, oncology, and pharmacology.

Publications per year

1999–2021

24

Publications

24

Transforming growth factor-β induces development of the TH17 lineage

Paul R. Mangan, Laurie E. Harrington, Darrell B. O’Quinn et al. · Nature · 2006 · 3K citations

, , +11

FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Sean Khozin, Gideon M. Blumenthal, Lijun Zhang et al. · Clinical Cancer Research · 2015 · 188 citations

, , +14

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 182 citations

, , +17

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or Fusions

Diana Bradford, Erin Larkins, Sirisha L. Mushti et al. · Clinical Cancer Research · 2020 · 167 citations

, , +12

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

Shakun Malik, V. Ellen Maher, Karen E. Bijwaard et al. · Clinical Cancer Research · 2014 · 139 citations

, , +14

1–5 of 24